ReviewFrontiers in endocrinology2023
Anoikis in phenotypic reprogramming of the prostate tumor microenvironment.
Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Human Group IIA Secreted Phospholipase AInternational journal of molecular sciences · 2026Review
- MircoRNAs as regulators of regulated cell death in cancer progression: a focus on ferroptosis, anoikis and pyroptosis.Frontiers in pharmacology · 2026Review
- Effect of TGF-β mediated phenotypic changes on prostate cancer cell anoikis response.Oncogene · 2025Article
- Anoikis resistance and cancer.BMC cancer · 2025Review
- The immune landscape of systemic inflammation in prostate cancer.Cancer biology & medicine · 2025Review
- Programmed Cell Death in Cancer.MedComm · 2025Review
- Anoikis-Related Genes Impact Prognosis and Tumor Microenvironment in Bladder Cancer.Molecular biotechnology · 2025Article
- Identification of Anoikis-Related Genes in Chronic Kidney Disease Based on Bioinformatics Analysis Combined with Experimental Validation.Journal of inflammation research · 2025Article
- The role and mechanisms of exosome microRNA in regulating metastasis within the tumor microenvironment of prostate cancer.Frontiers in oncology · 2025Review
- A thermo-sensitive hydrogel with prominent hemostatic effect prevents tumor recurrence via anti-anoikis-resistance.Journal of nanobiotechnology · 2024Article
- Epithelial-mesenchymal plasticity in cancer: signaling pathways and therapeutic targets.MedComm · 2024Review
- Article
- Obesity, dietary interventions and microbiome alterations in the development and progression of prostate cancer.Frontiers in immunology · 2024Review
- Identification of anoikis-related gene signatures and construction of the prognosis model in prostate cancer.Frontiers in pharmacology · 2024Article
- Therapy resistance in prostate cancer: mechanism, signaling and reversal strategies.Exploration of targeted anti-tumor therapy · 2024Review
- Exploring the Role of the Gut and Intratumoral Microbiomes in Tumor Progression and Metastasis.International journal of molecular sciences · 2023Review
- Microbiota and the landscape of the prostate tumor microenvironment.American journal of clinical and experimental urology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Prostate cancer is one of the most common malignancies in males wherein 1 in 8 men are diagnosed with this disease in their lifetime. The urgency to find novel therapeutic interventions is associated with high treatment resistance and mortality rates associated with castration-resistant prostate cancer. Anoikis is an apoptotic phenomenon for normal epithelial or endothelial cells that have lost their attachment to the extracellular matrix (ECM). Tumor cells that lose their connection to the ECM can die via apoptosis or survive via anoikis resistance and thus escaping to distant organs for metastatic progression. This review discusses the recent advances made in our understanding of the signaling effectors of anoikis in prostate cancer and the approaches to translate these mechanistic insights into therapeutic benefits for reducing lethal disease outcomes (by overcoming anoikis resistance). The prostate tumor microenvironment is a highly dynamic landscape wherein the balance between androgen signaling, cell lineage changes, epithelial-mesenchymal transition (EMT), extracellular matrix interactions, actin cytoskeleton remodeling as well as metabolic changes, confer anoikis resistance and metastatic spread. Thus, these mechanisms also offer unique molecular treatment signatures, exploitation of which can prime prostate tumors to anoikis induction with a high translational significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.